MedTrace Logo

Observational Study in CLL Patients Receiving BR

NCT02381899 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2019-02-01

No results posted yet for this study

Summary

The purpose of this observational study is to provide additional data to confirm the safety profile and efficacy of bendamustine and rituximab (BR) chemotherapy for chronic lymphocytic leukemia patients with significant comorbidities treated in routine clinical practice.

Conditions

Interventions

DRUG

Bendamustine and Rituximab

Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Sponsors & Collaborators

  • Czech CLL Study Group

    lead NETWORK

Principal Investigators

  • Martin Spacek, MD, PhD · Czech CLL Study Group

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-12-31
Completion
2018-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02381899 on ClinicalTrials.gov